Join
Live feed
·
INSIDERFilingvia Quantisnow
Climb Bio Inc. logo

Director Thomas Stephen Basil sold $1,366,820 worth of shares (100,000 units at $13.67) as part of a pre-agreed trading plan, decreasing direct ownership by 18% to 467,969 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
CLYM· Climb Bio Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CLYM (Climb Bio Inc.) and more on Quantisnow.